Product Banner

Cardiovascular Pharmaceuticals Market in India 2012

Cardiovascular Pharmaceuticals Market in India 2012

* Required Fields

  • Apr 20, 2012
  • 71 pages
  • Netscribes
Cardiovascular pharmaceuticals market in India is the second largest contributor to domestic pharmaceutical sales, contributing around 15.6%. Since India has a huge patient pool, the Indian market is characterized by a huge demand for cardiovascular drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the patient population, patent expiry of popular blockbuster drugs, increase in disposable income and introduction of newer and better drugs is helping the market to grow. The Indian Government, on its part has taken initiatives to reduce drug prices, has made certain reforms in the tax structure and has undertaken various control programmes. The market is expected to exhibit steady growth over the next few years.

The report begins with the introduction section which offers a brief insight into the major cardiovascular drug classes. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth.

An analysis of the drivers explains the factors for growth of the industry including increasing patient population, patent expiry of blockbuster drugs, increase in disposable income and introduction of newer and better drugs. The key challenges include strong competition between the different pharma companies and competition from complementary and alternative medicines.

The government initiatives section gives analyses the efforts to reduce drug prices, changes in the customs duty structure and the various control programmes undertaken by the Government.

A brief overview of the drug market value chain, drug regulations and patents is presented in the next section. It analyses the pharmaceutical value chain, and focuses on the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. A snapshot of different regulatory frameworks existing in the Indian pharma industry has been provided. The section also provides a list of important patent approvals for cardiovascular drugs.

The competition section gives overview of pharmaceutical companies in the country operating in the cardiovascular pharmaceutical industry. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario. It also incorporates the recent developments in the Cardiovascular Pharmaceutical industry.

The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares. The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares. Foray into the preventive care therapeutic segment will help the companies gain a competitive advantage over the others. Companies can focus on development of such cardiovascular drugs which can be used as preventive medicines, but without any side effects. Also, efficient marketing strategies are required to make both the physicians and the patients aware of such preventive medicines.
Table of Contents
Page 1: Executive summary

Page 2: Major drug classes of cardiovascular drugs

Market Overview
Page 3: Global Cardiovascular Pharmaceuticals Market - Overview, Size & Growth (Value: 2009-15e),
Page 4: Indian Cardiovascular Pharmaceuticals Market- Overview, Size & Growth (Value: 2010-2015e), Growth in Therapeutic segments

Drivers & Challenges
Page 5: Summary
Page 6-9: Drivers
Page 10: Challenges

Government Initiatives
Page 11: Summary
Page 12-13: Government Initiatives

Market value chain, regulation and patents
Page 14: Pharmaceutical value chain
Page 15: Phases of clinical trials
Page16-17: Drug regulations
Page 18: Regulatory frameworks
Page 19-20: List of patent approvals

Page 21- Market Competition - Porter's Five Forces Analysis
Page 22- 57: Major public players
Page 58- 69: Major private players
Page 70: Recent Developments

Strategic Recommendation
Page 71: Strategic Recommendations
List of Figures
Market Overview
1. Cardiovascular Pharmaceutical Market- Global Market Size and Growth (Value wise 2009 - 2015e)
2. Cardiovascular Pharmaceutical Market - India Market Size and Growth (Value-Wise, 2010 - 2015e)
3. Top pharmaceutical segments (Percentage wise 2010)

Drivers & Challenges
4. Deaths from CVDs (Value wise 2000 - 2025e)
5. Coronary heart disease patients (Value wise 2010 - 2015e)
6. Increasing per capita disposable income ( Value wise 2007 - 2011)

7. Financial Snapshot
8. Key Business segments (only Public Players)
9. Key Geographic segments (only Public Players)
Except GlaxoSmithKline Pharmaceuticals Limited
List of Tables
Market Overview
1. Top selling cardiovascular drugs 2010 - global market

Drivers & Challenges
2. Patent expiry date of drugs

Market Value Chain, Regulation and Patent
3. Tabular representation of drugs approved in recent past (2009- 2010)
4. Tabular representation of regulatory framework of Indian Pharmaceutical Industry
5. Tabular representation of USFDA patent approvals for cardiovascular drugs

6. Company profiles (All companies)
a. Company information
b. Products and services
c. Key people
d. Key Financial Performance Indicators
e. Key Ratios
Except for Pfizer Limited
f. Business Highlights
Companies Covered
1. AstraZeneca Pharma India Limited
2. Aventis Pharma Limited
3. Cipla Limited
4. Dr. Reddy's Laboratories Limited
5. GlaxoSmithKline Pharmaceuticals Limited
6. Lupin Limited
7. Merck Limited
8. Novartis India Limited
9. Pfizer Limited
10. Ranbaxy Laboratories Limited
11. Sun Pharmaceutical Industries Limited
12. Torrent Pharmaceuticals Limited
13. Bristol-Myers Squibb India Private Limited
14. Cadila Pharmaceuticals Limited
15. Intas Pharmaceuticals Limited
16. USV Limited